Zika virus-specific synthetic molecule can differentiate between prior infections with different flaviviruses

FHS
May 14, 2024
12:47 pm

A newly discovered Zika virus-specific synthetic molecule is capable of differentiating Zika-immune patient samples from samples of patients previously infected with the related dengue virus.

Insurer Will Launch ‘Gold Card’ Program to Skip Prior Authorization

Physicians frequently cite prior authorization requirements as a significant source of administrative burden. Now, UnitedHealthcare, one of the largest U.S. insurance companies, says it will

September 6, 2024

The U.S. hasn’t seen syphilis numbers this high since 1950. Other STD rates are down or flat

NEW YORK — The U.S. syphilis epidemic isn’t abating, with the rate of infectious cases rising 9% in 2022, according to a new federal government

January 30, 2024

Consolidated interim results as per June 30th,2023 – Biotech Investments

Vitruvia Medical AG / Key word(s): Half Year Results/Half Year Report Vitruvia Medical AG: Consolidated interim results as per June 30th,2023 29-Sep-2023 / 12:15 CET/CEST

September 30, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.